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For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section. n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
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For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.
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No software was used Data were analyzed using ImageJ version 1.48v (https://imagej.nih.gov/ij/), Excel 2013 and CellQuest Pro software program version 6.0 (BD Biosciences).
All data supporting the conclusions are available from the authors on reasonable request.
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Life sciences study design
All studies must disclose on these points even when the disclosure is negative. No data were excluded from the analyses.
All attempts at replication were successful. Each individual experiment was repeated independently with similar results at least three times.
Age/sex matched litter mates were assigned to groups by genotype. Groups were not randomized.
In vivo analysis was performed by experimenters who were blinded to the identity of the groups.
All antibodies (supplier name, catalog number/clone name, dilution) are provided in the Methods section under "Reagents and antibodies" as follows:
Polyclonal antibody against full-length Ndrg1 (1:1000) was a kind gift from Dr. Kokame (National Cerebral and Cardiovascular Center, Suita, Japan). We purchased anti-mouse VEGFR-2 antibody (1:25, ab10972) from Abcam (Cambridge, UK), and CF488 conjugated anti-goat IgG antibody (1:25, 20225) from Biotium (Hayward, CA), and Alexa Fluor® 488 anti-mouse CD102 (ICAM-2) antibody (1:200, 105609) and PE anti-mouse CD31 antibody (1:20, 102407) from BioLegend (San Diego, CA), FITC conjugated Mouse IgG2b,  Isotype Control (1:200, 559532) and PE conjugated Mouse IgG2a,  Isotype Control (1:20, 553457) from Becton-Dickinson (San Diego, CA) for flow cytometry analysis. We generated anti-NDRG1 antibody for Co-IP assay as described previously41 (1:500). We purchased mouse anti-PLC1 antibody (1:100, sc-7290) from Santa Cruz Biotechnology (Santa Cruz, CA), and rabbit anti-NDRG1 antibody (1:100, ab124689) from Abcam for PLA assay. We purchased the following antibodies from Cell Signaling Technology (Beverly, MA): anti-phospho-ERK1/2 (T202/Y204) (1:1000, 9106); anti-ERK1/2 (1:1000, 9102); antiphospho-AKT (S473) (1:2000, 4060); anti-AKT (1:1000, 9272); anti-NDRG1 (1:1000, 9408); anti-FGF receptor (FGFR)1 (1:1000, 9740); anti-phospho-PLC1 (Y783) (1:1000, 14008); anti-PLC1 (1:1000, 5690); anti-phospho-VEGFR2 (Y1175) (1:1000, 2478); anti-VEGFR2 (1:1000, 2479); anti-phospho-PKC (T505) (1:1000, 9374); and anti-PKC (1:1000, 9616). We purchased the anti-GAPDH antibody (1:5000, 2275-PC-100) from Trevigen (Gaithersburg, MD).
Primary antibodies were validated for use based on the position the antigen in SDS-PAGE gels. We also used the NDRG1 KO or siRNAs to specifically deplete endogenous protein to verify anti-NDRG1 antibodies. All other commercial antibodies were validated by manufacturers.
The cell lines used are described in the Methods section under "Cell culture" as follows:
We obtained murine RENCA cells from the American Type Culture Collection (Manassas, VA). We cultured cancer cells in RPMI-1640 medium (Nissui, Tokyo, Japan) supplemented with 10% FBS (Hyclone, Logan, UT). We cultured mouse lung ECs in endothelial cell basal medium (EBM-2) supplemented with the EGM-2MV Bullet Kit (15% FBS) (CC-3202; Lonza Walkersville Inc, Walkersville, MD). We purchased HUVECs from Lonza Walkersville Inc. and cultured them in EBM-2 supplemented with nature research | reporting summary Field-collected samples
Ethics oversight
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Human research participants
Policy information about studies involving human research participants
Population characteristics
Recruitment
Ethics oversight
Flow Cytometry Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation
Instrument Software the EGM-2 Bullet Kit (2% FBS) (CC-3162; Lonza Walkersville Inc). We passaged all cell lines for 6 months and they were not further tested or authenticated by the authors.
None of the cell lines used in this study was authenticated by the authors. For primary mouse lung endothelial cells, we checked the expression of vascular endothelial markers CD31, ICAM-2, VEGFR2 and VE-cadherin.
All cell lines were routinely tested negative for mycoplasma contamination.
No commonly misidentified cell lines were used.
We purchased the Ndrg1/ mice on a C57BL6 background from Laboratory Animal Resource Bank, National Institutes of Biomedical Innovation, Health and Nutrition (Osaka, Japan). In all our experiments we compared Ndrg1/ mice with age-(6-10 weeks) and gender-matched Ndrg1+/+ mice. We housed the mice in a specific-pathogen free room. We performed PCR analysis of DNA isolated from cut tail as described previously (Watari et al., 2016) .
The study did not involve wild animals.
The study did not involve field-collected samples.
The use of mice was following ethical regulations and was approved by The Animal Ethics Committee of Kyushu University (Approval numbers: A28-029-1 and A30-068-0).
We analyzed 5 patients newly diagnosed with breast cancer, who were treated between 2017 and 2018 at Kurume University Hospital (Kurume, Japan).
N/A
The use of human breast tumor specimens was approved by the Institutional Review Board of Kurume University Hospital (Kurume, Japan) (Approval number: 18235). The study using human tumor tissue samples conforms to the principles of the Declaration of Helsinki and the need for written informed consent was waived for this retrospective study.
We detached mouse lung ECs with 5 mM EDTA and washed them in PBS, prior to flow cytometry analysis. We stained mouse lung ECs in suspension containing 1000000 cells/100 l in incubation buffer (0.5% BSA in PBS) with anti-VEGFR2 mAb or FITCconjugated Mouse IgG1 Isotype Control (555748; Becton-Dickinson) for 25 min at 4°C, and thereafter incubated them in CF488 conjugated anti-goat IgG antibody for 20 min at 4°C. For CD31 and ICAM-2 staining, we stained mouse lung ECs in suspension containing 1×1000000 cells/100 l in incubation buffer (0.5% BSA in PBS) with Alexa Fluor® 488 anti-mouse ICAM-2 antibody (1:200, BioLegend) and PE anti-mouse CD31 antibody (1:20, BioLegend) or FITC conjugated Mouse IgG2b,  Isotype Control (1:200, 559532, Becton-Dickinson) and PE conjugated Mouse IgG2a,  Isotype Control (1:20, 553457, Becton-Dickinson) for 25 min at 4°C. We used a FACSCalibur system (Becton-Dickinson) to acquire data. We used the CellQuest Pro software program (BD Biosciences, San Jose, CA) to analyze the data.
We used the BD FACSCalibur with 3 lasers machine to collect and analyze all the FACS results in the manuscript.
We used the BD CellQuest Pro software version 6.0 to collect and analyze the flow cytometry data.
